New hope for ALS? experimental drug TP04HN106 enters human trials
NCT ID NCT06726577
First seen May 25, 2026 · Last updated May 25, 2026
Summary
This study tests an experimental drug called TP04HN106 in 60 people with ALS. Half get the drug, half get a placebo (salt water), and later everyone can receive the drug. The goal is to see if it slows down the disease and is safe. All participants also take standard riluzole tablets.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AMYOTROPHIC LATERAL SCLEROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Affiliated Hospital of Soochow University
RECRUITINGSuzhou, Jiangsu, 215000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.